• Transcription profiles associated with mutated MYD88, CXCR4, ARID1A, abnormal cytogenetics including 6q2, and familial WM are described.
Introduction
Whole-genome sequencing identified several highly recurring somatic mutations in patients with Waldenström macroglobulinemia (WM). 1, 2 In over 90% of WM patients, a single point mutation at NM_002468: c.978T.C (rs387907272) in MYD88 is found, resulting in a p.Leu265Pro (L265P) amino acid change. 1, 3 MYD88 is an adaptor for Toll-like (TLR) and interleukin 1 (IL1) receptors, and the MYD88 L265P mutation triggers constitutive activation of NF-kB through IRAK and BTK. 1, 4, 5 Mutated MYD88 WM patients show greater overall survival and clinical responses to the BTK inhibitor ibrutinib. 6, 7 Activating CXCR4 frameshift or nonsense mutations in the C-terminal tail are found in 30% to 40% of WM patients, are primarily subclonal, and almost always associated with MYD88 L265P . 2, 3, 8 These somatic mutations are similar to the causal germ line variants that underlie WHIM (warts, hypogammaglobulinemia, infection, and myelokathexis) syndrome. 2, 9 In WM, somatic CXCR4 mutations (CXCR4 WHIM ) are determinants of disease presentation, as well as resistance to ibrutinib. 3, 6, 10 Somatic mutations in ARID1A, a member of the SWItch/sucrose nonfermentable family and epigenetic regulator, are also found in 20% of WM patients. Gene losses affecting NF-kB signaling (ie, HIVEP2, TNFAIP3), as well as the ARID1A homolog ARID1B are present in most WM patients. 2, 11 Deletions in chromosome 6q with and without concurrent 6p amplifications, trisomy 3, and amplifications of 3q, as well as trisomy 4, are also commonly found in WM. [12] [13] [14] Previous array-based gene expression studies of WM were largely conducted prior to these genomic discoveries and therefore the effects of recurrent somatic events on transcriptional regulation remain to be clarified. [15] [16] [17] We therefore performed next-generation RNA sequencing in 57 WM patients and compared findings to sorted healthy donor-derived nonmemory (CD19 1 CD27 2 ) and memory (CD19 1 CD27 1 ) B cells. The latter represent the B-cell population from where most cases of WM are thought to be derived. 18, 19 Methods
Sample selection and characterization
Bone marrow (BM) aspirates were collected from 57 patients with the WM consensus diagnosis. 20 Participants provided informed consent for sample collection per the Dana-Farber/Harvard Cancer Center Institutional Review Board. WM cells were isolated by CD19
1 magnetic-activated cell sorting (MACS) ) using a memory B-cell isolation kit (Miltenyi Biotec). RNA and DNA were purified using the AllPrep mini kit (Qiagen, Valencia, CA). Most samples were previously characterized by whole-genome sequencing and all samples were screened for MYD88 and CXCR4 gene mutations by Sanger sequencing.
2 MYD88 L265P and CXCR4 c.1013C.G and c.1013C.A mutations were analyzed by allele-specific polymerase chain reaction (PCR) as previously described. 8, 21 Next-generation sequencing and analysis Transcriptome profiling was conducted by the Center for Cancer Computational Biology at the Dana-Farber Cancer Institute (Boston, MA) using the NEBNext Ultra RNA library prep kit (New England BioLabs, Ipswich, MA). The paired-end samples were run 2 per lane for 50 cycles on an Illumina HiSeq (Illumina, San Diego, CA). Read-level data are available through dbGAP accession (applied). Reads were aligned to KnownGene HG19/GRCh37 reference using STAR (Spliced Transcripts Alignment to a Reference). 22 Genes with mean raw read counts of ,10 were not analyzed, leaving 16 888 expressed genes for analysis. Read counts per gene were obtained using featureCounts from Rsubread, and analyzed using voom from the edgeR/limma Bioconductor packages in R (R Foundation for Statistical Computing, Vienna, Austria). [23] [24] [25] [26] [27] Differential expression models accounted for sex, prior treatment, as well as MYD88 and CXCR4 mutation status. A false discovery rate (FDR) cutoff of 10% was used to determine significant differentially expressed genes. Functional enrichment analysis was conducted using Ingenuity Pathway Analysis (Qiagen). Clustering and correlation analysis was conducted using the variance stabilizing transformation of the count data from the Bioconductor DESeq2 package. 28 In all other cases, estimates of gene expression levels are represented in transcripts per million (TpM). Log-fold change (LFC) listed in text and tables are derived from the limma analysis.
CXCR4 transduced cell lines and gene expression analysis
Previously described BCWM.1 and MWCL-1 cell lines transduced to express CXCR4 with or without activating mutations observed in WM patients were used to model CXCR4-stimulated gene expression changes in WM. 10 Briefly, CXCR4 complementary DNA (cDNA) transcripts were subcloned into plenti-internal ribosomal entry site (IRES)-green fluorescent protein (GFP) vectors, and stably transduced using a lentiviral system. 4 In addition to wild-type (WT) CXCR4, vectors with the mutations c.1013C.G (p.Ser338*), c.932_933insT (p.Thr311fs), and c.1030_1041delinsGT (p.Ser344fs) were generated. Cell lines were stimulated with 50 nM of the CXCR4 ligand CXCL12 (SDF1A) (R&D Systems, Minneapolis MN) for 2 hours. RNA from each sample was extracted at baseline and at 2 hours. Gene expression was assessed using Affymetrix Human Gene ST 2.0 arrays (Affymetrix, Santa Clara, CA). Array data are archived in the Gene Expression Omnibus database (accession number GSE83150). Array data were analyzed using the Oligo and limma R bioconductor packages.
24,29

Statistical analysis
Random forest analysis was implemented using the cforest function in the party package in R. 30 Models were constructed using the cforest_unbiased function with 20 predictors per tree over 10 000 trees. As variable importance scores of nonsignificant genes are distributed around zero, genes were further filtered for those with permutation importance scores greater than the absolute value of the lowest scoring predictor. For reproducibility, the random seed for the analysis was set to 265. Principal component analysis (PCA) was conducted using R's prcomp, Pearson's product-moment coefficient was used for correlation studies, and cohort mean values were compared using the Wilcoxon rank sum test.
Gene expression, sequencing, and methylation studies Gene expression results were validated by using TaqMan gene expression assays Hs01027785_m1 (DUSP4), hs00244839_m1 (DUSP5), Hs00243182_m1 (RGS13), Hs00892674_m1 (RGS16), Hs00698249_m1 (RASSF6), Hs00396602_m1 (WNK2), Hs00924602_m1 (PRDM5) (Thermo Fisher Scientific, Waltham MA). Methylation-specific PCR assays for RASSF6, WNK2, and PRDM5 were conducted on bisulfite-converted DNA using previously established protocols.
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Results
The clinical characteristics for the 57 WM patients are presented in Table 1 . The distribution of somatic mutations and cytogenetic findings in these patients was similar to those previously described. 34 The top 500 differentially expressed genes for each comparison discussed below are available as a part of the supplemental Data (available on the Blood Web site).
Comparing WM to healthy donor B cells
Comparison of WM and HD samples generated a list of 13 571 differentially expressed genes. To gain further insight into these gene expression differences, this gene list was sorted by absolute log 2 fold change, revealing a marked upregulation of DNTT, RAG1, RAG2, and IGLL1 in WM samples. These genes have important functional roles in VDJ recombination and B-cell receptor (BCR) signaling. Other upregulated genes relevant to WM biology and pathogenesis included CXCL12, VCAM1, CD5L, BMP3, and IGF1. Among the top 40 differentially expressed genes sorted by absolute expression in WM as measured in TpM were CXCR4, the WM prognostic marker B2M, and 2 genes related to BCR signaling: CD79A and CD79B. To examine transcriptional similarities between the samples in an unbiased manner, multidimensional scaling of the 500 genes with the highest variance was used to best represent the data in 2 dimensions ( Figure 1A WT genotyped WM patient samples was observed. To examine whether the patterns of expression were similar between HD samples and patient mutational groups, a correlation coefficient based on overall gene expression was generated for each sample-to-sample comparison. These values were averaged together by HD PB/MB cell type and WM MYD88/CXCR4 genotype to show the extent of correlation between groups ( Figure 1B Figure 1C ; supplemental Figure 1 ). To better understand the role of B-cell differentiation in WM, we analyzed 19 genes linked to the transition from MB to plasmablasts and plasma cells ( Figure 1D) . 35, 36 Many of these genes were not only significantly differentially expressed between HD and WM samples, but between WM patients based on MYD88 and CXCR4 mutation status suggesting reduced differentiation in both MYD88 L265P CXCR4 WHIM and, in particular, MYD88
WT CXCR4 WT samples. Separation of patient samples by genotype can be seen in the PCA of these 19 genes in Figure 1E . BCL2 and BCL2L1 were upregulated in all WM samples, however, analysis of the larger BCL2 family revealed stratification of samples by HD cell type and MYD88/CXCR4 mutation status (supplemental Figure 2) . The proapoptotic BAX gene was downregulated in WM samples and PMAIP1 was uniquely upregulated in MYD88 L265P CXCR4 WT WM.
Transcriptional effects of CXCR4
WHIM
Restricting the analysis to WM patients, PCA of the top 500 high variance genes accounted for 41% of the overall variability within the first 2 components (Figure 2A 
CXCR4
WHIM patients followed a pattern resembling HD samples, despite carrying the MYD88 L265P mutation ( Figure 2B ). The top predicted upstream regulator for this gene signature was the inhibition of lipopolysaccharide signaling ( Figure 2C ). To further explore how CXCR4 mutations modulate MYD88 signaling in WM, the gene signature was filtered for genes involved in TLR signaling.
MYD88
L265P CXCR4 WHIM patients showed downregulation of the lipopolysaccharide receptors TLR4 and NOD2, and upregulation of TLR7 and IRAK3 (supplemental Figure 3A) . The most significant results associated with CXCR4 mutation status were silencing of genes in patients with MYD88 L265P CXCR4 WHIM that were elevated in MYD88 L265P CXCR4 WT patients (supplemental Figure 3B ).
Promoter methylation studies
To investigate the role of methylation in genes differentially expressed based on CXCR4 and MYD88 mutation status, 3 such genes were selected for screening based on their regulation by promoter methylation in other malignancies: PRDM5, WNK2, and RASSF6. 32, 33, 37 Gene expression was validated by PCR in HD B-cell samples as well as in MYD88 and CXCR4 genotyped WM patient samples (supplemental Figure 4A ). 
CXCR4
WT patients. To determine relevance of these methylation sites in hematologic malignancies, WM, B-cell lymphoma, and myeloma cell lines were assessed for promoter methylation using methylation-specific PCR assays (supplemental Figure 4B) . Sixteen MYD88 and CXCR4 genotyped primary WM patient samples and 4 healthy donor B-cell samples were then tested (supplemental Figure 4C) Table 1 ). In 8 of 16 (50%) of these genes, the direction of the change relative to MYD88
L265P
CXCR4
WT was same as that observed in the patient samples. However, it was the genes whose direction of change was opposed that revealed the most about the underlying biology. These discordant genes were enriched for suppressors of MAPK and G-protein signaling downstream of CXCR4. They were preferentially induced in CXCR4 WHIM cell lines by CXCL12 stimulation and suppressed in MYD88 L265P CXCR4 WHIM patient samples. 10, 38 Interrogation of these dual specificity phosphatases (DUSP) and regulator of G-protein signaling (RGS) genes revealed RGS1, RGS2, RGS13, DUSP1, DUSP2, DUSP4, DUSP5, DUSP10, DUSP16, and DUSP22 were all significantly suppressed in MYD88
patients. Expression in patients of DUSP4, DUSP5, RGS13, and RGS16, which were selected for validation based on the cell line studies, can be seen in supplemental Figure 5A . The increased expression of these genes in CXCR4 WHIM compared with CXCR4 WT transduced lines was validated by real-time PCR (supplemental Figure 5B ). Dose-response curves for these genes following CXCL12 stimulation was conducted in transduced BCWM.1 and MWCL-1 (supplemental Figure 5C ).
Gene signatures associated with other clinical and genomic features
For the 5 patients with ARID1A mutations, 16 differentially expressed genes were observed. The ARID1A-mutated population also demonstrated elevated BM disease infiltration (median, 90%; range, 70%-95%) when compared with non-ARID1A-mutated patients (median, 58%; range, 5%-95%; P 5 .0259). No statistically significant gene expression changes were observed in the 4 patients with CD79B mutations. Analysis based on somatic cytogenetic abnormalities included deletion of chromosome 6q (131 genes), amplification of chromosome 6p (65 genes), amplification of chr3q including trisomy 3 (11 genes), and trisomy 4 (776 genes). A distinct gene expression signature for 263 genes was also observed in the 3 patients who had first-degree relatives with WM. No statistically significant differences in gene expression were observed based on presence of extramedullary disease, elevated B 2 M levels (.3 mg/dL), or International Waldenström Macroglobulinemia Prognostic Scoring System score.
To identify genes associated with relevant WM clinical parameters, all genes were tested for correlation with serum immunoglobulin M (IgM) levels, hemoglobin, and BM disease involvement. After filtering the results by significance (P , .05) and the absolute value of the correlation estimate .0.3, 312 genes were found to be associated with IgM, 965 with hemoglobin, and 3738 with BM involvement. These genes were combined with MYD88/CXCR4 genotype, age, sex, and treatment status in a random forest regression analysis for the first 37 study patients, leaving the remaining 20 patients for 
BCL7A
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cross-validation. Filtering genes/predictors by variable importance score resulted in 40, 236, and 143 associated genes for IgM, BM, and hemoglobin, respectively (supplemental Figure 6 ). Functional analysis was conducted on each gene list and top genes from each group were selected based on biological significance. The 40 genes associated with IgM were predicted to be downstream of IL6 signaling (P 5 .0018) and included many genes of WM pathogenic interest including TNFRSF17, BMP3, IRS1, and CEPZOS ( Figure 3A ). Many genes relevant to WM biology, including CXCL13, TP53, CXCR4, MYD88, CDC23, and AKAP1, were associated with BM disease involvement ( Figure 3B ). Although MYD88 and CXCR4 were both correlated to BM disease involvement (r 5 20.50; P , .0001 and r 5 0.46; P 5 .0003, respectively), they were negatively correlated with each other (r 5 20.46; P 5 .0004). As shown in supplemental Figure 7 , this relationship may be influenced by MD88/CXCR4 mutation status. The gene list associated with hemoglobin included CXCL13, as well as PIK3AP1, PIK3CD, AJUBA, and OS9 ( Figure 3C ). Based on these findings, CXCL13 was included in an independent serum cytokine profiling study of 86 WM patients that validated the CXCL13 correlation between BM (Spearman r 5 0.562; P 5 2.192 3 102 ).
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Analysis of mutant allele burden
The percentage of reads supporting the mutant allele relative to WT allele was calculated for MYD88, CXCR4, ARID1A, and CD79B in the BLOOD, 11 AUGUST 2016 x VOLUME 128, NUMBER 6 TRANSCRIPTOME OF WALDENSTRÖM MACROGLOBULINEMIA 833
For personal use only. on May 23, 2017 . by Steven Treon www.bloodjournal.org From RNA sequencing data. Although the relevant mutations were observed in the RNA in all cases, many samples with CXCR4 WHIM mutations had mutant allele burdens in excess of 50%, an unexpected finding for a typically subclonal variant. 8 As there can be differences in mapping efficiencies between indels and single-nucleotide variants, MYD88
L265P allele burden was then compared with the CXCR4 WHIM allele burden at the RNA level for the 11 patients with nonsense CXCR4 somatic mutations ( Figure 4A ). RAG1  RAG2  IGF1  BMP3  CD5L  CXCL12  VCAM1  CXCR4  B2M  BCL2  BAX   IL17RB  GPER  WNT5A  IGF1  WNK2  PRDM5  CABLES1  CXXC4  CDKN1C  LGALS3BP  PMAIP1  TP53I11   IL15  ERRFI1  NOD2  TLR4  TLR7  IRAK3  CXCR7  TSPAN33  PIK3R5  PIK3CG   RGS1  RGS2  RGS13  DUSP1  DUSP2  DUSP4  DUSP5  DUSP10  DUSP16  DUSP22   IL6  IRAK2  TNFAIP3  NFKBIZ  NFKB2  TIRAP  PIM1  PIM2  CD40  PTBP3   CD86  CXCR3  IGF1R AKT2 PIK3AP1 Figure 5 . Summary of key gene expression differences. Gene expression levels for all study samples are shown depicting key differences for WM vs normal B-cell samples as well as WM patient intrapatient differences based on MYD88 and CXCR4 genotype. The heat map represents log 2 transformed TpM values with median and range TpM values listed for each relevant comparator. P values have been adjusted for multiple hypotheses testing using the Benjamini-Hochberg FDR.
true for CXCR4 mutations ( Figure 4B ). This reduced expression of MYD88 L265P at the RNA level was also observed in some CXCR4
WT patients.
Discussion
This study represents the first profile of the transcriptional landscape of WM by next-generation sequencing. Among the most striking findings was a .7.8 log-fold upregulation of VDJ recombination related genes including RAG1, RAG2, and DNTT in WM patients samples (Figures 5 and 6 ). The class switch recombination gene AICDA was not observed at meaningful levels consistent with the lack of immunoglobulin class switching in WM. The overexpression of RAG1 and RAG2 is notable because specific somatic mutation patterns such as deletions in BTG1 and ETV6 are associated with their aberrant expression, and are commonly observed in WM patients. 2, 40, 41 The universal expression of CXCR4 and the upregulation of its ligand CXCL12 are suggestive of autocrine/paracrine signaling. CXCR4 activation has been reported to increase cell adhesion to VCAM1 via VLA4, and VCAM1 was the eighth most upregulated gene relative vs HD samples. 42, 43 Taken together, these findings suggest that VCAM1, CXCR4, and CXCL12 may facilitate the homotypic WM cell clustering observed in the BM of many WM patients. Likewise, IGF1, an inducer of AKT1 survival signaling in WM, was a top hit among the most upregulated genes. IGF1 and its receptor IGF1R may therefore be potential therapeutic targets in WM and warrant further investigation. 44 Despite previous studies suggesting that WM was derived from MB, we did not observe increased similarity at the transcription level for MB relative PB as shown in Figure 1B, • and CXCR4 interactions are also listed.
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For personal use only. WT genotype strongly upregulate a number of surface receptors and signaling molecules including IL17RB, GPER1, WNT5A, and IGF1. IL17RB signaling may provide an additional source of NF-kB activation whereas GPER1 and IGF1 activate AKT1 and MAPK signaling in marginal zone lymphoma and WM, respectively. 44, 51, 52 However, WNT5A is a suppressor of B-cell proliferation. 53 Many of the genes upregulated in the MYD88 L265P CXCR4
WT patient cohort such as PMAIP1, WNK2, PRDM5, CABLES1, CXXC4, and CDKN1C are tumor suppressors that either promote apoptosis, inhibit cell cycle, or block MAPK signaling. [54] [55] [56] [57] [58] Normalization of MYD88
L265P
-associated tumor suppressor expression in CXCR4-mutated WM patients may provide the clearest explanation for the selective inhibition of MYD88 signaling observed in CXCR4 WHIM patients. This yin-and-yang relationship between MYD88 and CXCR4 is further supported by the modulation of allele specific transcription, decreasing and increasing the mutation allele burden of each gene, respectively. CXCR4 and MYD88 total transcription levels were negatively correlated and inversely predictive of BM disease involvement. Although aberrant promoter methylation of WNK2 and PRDM5 was prominent in MYD88 WT CXCR4
WT samples, it did not explain the low levels of WNK2 and PRDM5 observed in patients with CXCR4 WHIM mutations, thereby strengthening the case that these findings are related to CXCR4 WHIM signaling rather than unrelated epigenomic events. 62 The fact that DUSP2, DUSP4, DUSP5, RGS13, and ERRFI1 were all significantly induced by CXCL12 in CXCR4 WHIM vs CXCR4 WTtransduced lines supports a role for these genes as negative regulators of CXCR4 signaling and may have implications for MYD88 MAPK signaling as well. 63, 64 This is similar to a number of secondary events such as MYBBP1A mutations and deletions of TRAF3, TNFAIP3, and HIVEP2, which are thought to represent loss of negative regulators for NF-kB signaling in WM. 2, 11, 65 The mechanism(s) by which negative regulators of CXCR4 signaling are lost in patients with CXCR4
WHIM mutations remain to be clarified warranting further investigation.
Of the 1155 genes that were differentially expressed between MYD88 L265P and MYD88 WT patients, 552 were not observed in the WT patient expression was quite heterogeneous indicating pathogenetic diversity in this population. Large-scale genomic exploration will invariably be needed to help clarify the genetic basis for MYD88
WT WM disease. Regardless, a clear downregulation of genes associated with NF-kB signaling including IL6, IRAK2, TNFAIP3, NFKBIZ, NFKB2, TIRAP, PIM1, and PIM2 was observed in these patients. Other genes of interest included the downregulation of CD40, and upregulation of PTBP3, CD86, and CXCR3. Notably, IGF1R, PIK3AP1, and AKT2 were all upregulated, suggesting a reliance on PIK3 signaling. The antiapoptotic gene BCL2, known to play an important role in WM, was overexpressed expressed in all patient samples while the proapoptotic BAX was underexpressed, suggesting a mechanism independent of the MYD88 and CXCR4 mutations. [65] [66] [67] Somatic mutations in ARID1A were associated with increased CXCL13, as well as increased BM infiltration. CXCL13 has not been previously described in WM and was also a strong predictor of BM disease involvement and hemoglobin levels. CXCL13 may also play a role in mast cell recruitment. 68 Mast cells can be observed admixed with the WM B cells in patient BM histology and are thought to play an important supportive role in the tumor microenvironment of WM. 69 Deletions of chromosome 6q were associated with over 131 differentially expressed genes. Levels of previously identified target genes such as the NF-kB negative regulator HIVEP2, as well as BCLAF1, FOXO3 and ARID1B were all suppressed in the presence of 6q deletions. 2 Although only 3 patients had strong familial predisposition to WM, these patients demonstrated significant dysregulation of several cancerassociated genes including RB1, STAT5B, ZNF300, MAPK9, and NFKB1.
These studies highlight the pivotal roles of MYD88 and CXCR4 signaling in WM. CXCR4 mutations appear to function primarily as dampeners of negative regulators that are upregulated in response to mutant MYD88 signaling. The upregulation of the ligand, adhesion targets, and CXCR4 itself in all WM patients provides evidence for uniform CXCR4 dysregulation in WM and supports the development of CXCR4 antagonists for WM therapy. The upregulation of PIK3 pathway members and the increased promoter methylation in MYD88
WT patients creates a strong rationale for preclinical studies of PIK3 inhibitors and demethylating agents in this population. The upregulation of BCL2 across all WM patient genotypes also supports the development of BCL2 antagonists. Finally, CXCL13 is highly expressed by WM cells, and its expression correlates with important clinical parameters. Further studies to delineate therapeutic targeting of this cytokine in WM are warranted. 
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